New drugs in gastrointestinal stromal tumors

主旨 医学 伊马替尼 瑞戈非尼 靶向治疗 癌症研究 酪氨酸激酶 间质细胞 药理学 间质瘤 内科学 癌症 受体 结直肠癌 髓系白血病
作者
Javier Martín‐Broto,David S. Moura
出处
期刊:Current Opinion in Oncology [Lippincott Williams & Wilkins]
卷期号:32 (4): 314-320 被引量:18
标识
DOI:10.1097/cco.0000000000000642
摘要

Purpose of review Tyrosine kinase inhibitors (TKIs) are the backbone for advanced gastrointestinal stromal tumor (GIST) treatment. The increasing knowledge concerning the structure and the changing conformational status because of some mutations in KIT and PDGFRα, allowed the development of new efficient compounds, with the main goal to overcome resistance in GIST. This review summarizes the latest developments in the treatment of GIST patients. Recent findings Amongst the several TKIs currently being studied in GIST, ripretinib, avapritinib and crenolanib had shown promising potent activity in preclinical studies and clinical trials. Ripretinib is a type II inhibitor that exerts its main action in the switch pocket of the activation loop, by mimicking the inhibition exerted by the regulatory region in this domain. Ripretinib is considered the new standard in the fourth line in advanced GIST. Avapritinib is a type I inhibitor synthesized to exerts its activity in the active conformation of the activation loop of KIT and PDFGRα. The relevant activity reported with avapritinib in patients carrying the D842 v mutation represents, for first time, an active therapeutic option in this resistant mutant. Crenolanib is a type I selective inhibitor of PDGFRα-resistant mutants, mainly D842 V, which is currently under clinical trial. Summary New potent TKIs are being approved, adding value to the already three registered drugs. Other agents, such as MEK inhibitors, immunotherapy and TRK-targeted therapy are potential new options in specific subsets of GIST patients.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
元谷雪发布了新的文献求助10
1秒前
思源的应助被英英采纳,获得10
1秒前
1秒前
xinxih完成签到,获得积分10
1秒前
1秒前
合法的天空完成签到,获得积分10
1秒前
谨慎的从灵完成签到,获得积分10
2秒前
2秒前
自由的惮完成签到,获得积分20
3秒前
3秒前
xiaoxiao33完成签到,获得积分10
4秒前
5秒前
烛黎完成签到,获得积分10
6秒前
YaoHui完成签到,获得积分10
6秒前
6秒前
66完成签到,获得积分10
7秒前
孔晓辉完成签到,获得积分20
7秒前
7秒前
慕青的应助被GeoGou812采纳,获得30
8秒前
wcl完成签到,获得积分10
8秒前
8秒前
薄荷薄荷发布了新的文献求助30
8秒前
新XX完成签到,获得积分10
8秒前
wy.he完成签到,获得积分0
8秒前
高挑的白旋风完成签到,获得积分10
8秒前
sjy完成签到,获得积分20
9秒前
essieyang发布了新的文献求助10
9秒前
9秒前
美满的问儿完成签到,获得积分10
9秒前
super chan发布了新的文献求助10
10秒前
11秒前
谦让晓露as完成签到,获得积分10
11秒前
11秒前
台台a发布了新的文献求助30
11秒前
赘婿的应助被辛勤的乌采纳,获得10
12秒前
fanzixuan完成签到,获得积分20
12秒前
Connor完成签到,获得积分10
12秒前
13秒前
13秒前
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology)求助 1000
Encyclopedia of Modern Artificial Intelligence 1000
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8153573
求助须知:如何正确求助?哪些是违规求助? 9550279
关于积分的说明 21697424
捐赠科研通 7742161
什么是DOI,文献DOI怎么找? 3425546
关于科研通互助平台的介绍 2550636
邀请新用户注册赠送积分活动 2469181